Mahrous O Ahmed

King Saud University, Ar Riyāḑ, Ar Riyāḑ, Saudi Arabia

Are you Mahrous O Ahmed?

Claim your profile

Publications (3)5.8 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this work was to study the ability of beta-cyclodextrin (beta-CD) or hydroxypropyl beta-cyclodextrin (HP-beta-CD) to ameliorate the induction of gastric ulcers by a nonsteroidal anti-inflammatory drug, indomethacin or piroxicam, in rats exposed to restraint and hypothermic stress at 4 degrees C. Using oral gavage, rats fasted for 72 h were administered the equivalent of a 100 mg/kg dose of the assigned drug, alone or with the designated cyclodextrin (CD). The rats were placed in suitable rodent restrainers and then placed inside a ventilated refrigerator maintained at a temperature of 4 degrees C. Six hours later, each animal was removed, anaesthetized with ether, and the abdomen opened. Each stomach was removed, opened along the greater curvature and gently rinsed with isotonic saline solution. The induced gastric ulcers were examined and assessed with the help of a 10x binocular magnifier. Pronounced and marked gastric ulceration with complete loss of the mucosa, extensive deposition of fibrin and dense neutrophilic infiltrate were observed in rats treated with each of the drugs alone. Treatment with indomethacin or piroxicam alone induced ulcer indices of 26 +/- 2.3 or 14 +/- 1.8, respectively. However, beta-CD and HP-beta-CD each significantly suppressed ulceration due to restraint and cold stress. Rats treated with indomethacin or piroxicam in the presence of either beta-CD or HP-beta-CD exhibited normal tissues. Therefore, beta-CD and HP-beta-CD act as protective agents against gastrointestinal disorders produced by restraint and cold stress, even with the added stress from administration of either indomethacin or piroxicam.
    International journal of medical sciences 07/2010; 7(4):232-9. · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to prepare and evaluate dried yeast tablets using both direct compression and dry granulation techniques in comparison with the conventional wet granulation as well as commercial product. Wet granulation technique is not favorable for producing the yeast tablets due to the problems of color darkening and the reduction of the fermentation power of the yeast as a result of the early start of the fermentation process due to the presence of moisture. Twenty six formulae of dried yeast tablets were prepared and evaluated. Certain directly compressible vehicles were employed for preparing these tablets. The quality control tests (weight uniformity, friability, disintegration time and hardness) of the prepared dried yeast tablets were performed according to B.P. 1998 limits. All batches of the prepared tablets complied with the B.P. limits of weight uniformity. Moreover, small values of friability % (1% or less) were obtained for all batches of dried yeast tablets with acceptable hardness values, indicating good mechanical properties which can withstand handling. On the other hand, not all batches complied with the limit of disintegration test which may be attributed to various formulation component variables. Therefore, four disintegrating agents were investigated for their disintegrating effect. It was found that the method of preparation, whether it is direct compression, dry granulation or wet granulation, has an effect on disintegration time of these dried yeast tablets and short disintegration times were obtained for some of the formulae. The shortest disintegration time was obtained with those tablets prepared by direct compression among the other techniques. Therefore, the direct compression is considered the best technique for preparation of dried yeast tablets and the best formula (which showed shorter disintegration time and better organoleptic properties than the available commercial yeast tablets) was chosen. Drug content for dried yeast granular powder, and the chosen best prepared formula, was determined by gas chromatography (GC). It was found that this formula gave the same alcohol content produced by an equal amount of the dried yeast granular powder. This result in conjunction with weight uniformity indicated drug content uniformity of the prepared dried yeast tablets.
    European Journal of Pharmaceutics and Biopharmaceutics 09/2007; 67(1):253-9. DOI:10.1016/j.ejpb.2006.12.011 · 4.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this work was to improve the dissolution rate of albendazole (ABZ) by preparing its microparticles with certain hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and polyvinyl pyrrolidone (PVP) using spray drying technique. Microparticles of ABZ with these polymers were prepared in different ratios of 1:1, 1:2, and 1:4 by spray drying technique. Morphology and characterization of the prepared ABZ microparticles was studied and photographed using a biological microscope and examined by scanning electron microscope. Smooth surface and spherical microparticles of ABZ were detected by these methods which indicating the coating of drug crystals by the studied polymers. Physicochemical properties of drug alone and its spray dried microparticles were investigated using differential scanning calorimetry (DSC) and powder X-ray diffractometry (PXRD). DSC and PXRD analysis showed that ABZ transformed from the crystalline state to amorphous state by spray drying with these polymers as confirmed by disappearance of its melting peak and characteristic crystalline peaks. Dissolution rate of ABZ from the prepared microparticles was determined and compared to its corresponding physical mixtures. Results have shown that the dissolution rate of ABZ has been enhanced extremely from its spray dried microparticles and reached 100 % as compared to the corresponding physical mixtures. This indicates the success of spray drying technique for improvement of ABZ dissolution. Moreover, it was found that the
    Scientia Pharmaceutica 06/2007; 75(2):63-79. DOI:10.3797/scipharm.2007.75.63